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Abstract
Background: Many neuromuscular blockers act as negative allosteric modulators of muscarinic
acetylcholine receptors by decreasing affinity and potency of acetylcholine. The neuromuscular
blocker rapacuronium has been shown to have facilitatory effects at muscarinic receptors leading
to bronchospasm. We examined the influence of rapacuronium on acetylcholine (ACh) binding to
and activation of individual subtypes of muscarinic receptors expressed in Chinese hamster ovary
cells to determine its receptor selectivity.
Results:  At equilibrium rapacuronium bound to all subtypes of muscarinic receptors with
micromolar affinity (2.7-17 μM) and displayed negative cooperativity with both high- and low-
affinity ACh binding states. Rapacuronium accelerated [3H]ACh association with and dissociation
from odd-numbered receptor subtypes. With respect to [35S]GTPγS binding rapacuronium alone
behaved as an inverse agonist at all subtypes. Rapacuronium concentration-dependently decreased
the potency of ACh-induced [35S]GTPγS binding at M2 and M4 receptors. In contrast, 0.1 μM
rapacuronium significantly increased ACh potency at M1, M3, and M5  receptors. Kinetic
measurements at M3 receptors showed acceleration of the rate of ACh-induced [35S]GTPγS binding
by rapacuronium.
Conclusions: Our data demonstrate a novel dichotomy in rapacuronium effects at odd-numbered
muscarinic receptors. Rapacuronium accelerates the rate of ACh binding but decreases its affinity
under equilibrium conditions. This results in potentiation of receptor activation at low
concentrations of rapacuronium (1 μM) but not at high concentrations (10 μM). These
observations highlight the relevance and necessity of performing physiological tests under non-
equilibrium conditions in evaluating the functional effects of allosteric modulators at muscarinic
receptors. They also provide molecular basis for potentiating M3  receptor-mediated
bronchoconstriction.
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Background
Five subtypes of muscarinic acetylcholine receptors that
belong to class A of G-protein coupled receptors have
been identified [1]. The primary response of stimulation
of the M2 and M4 subtypes of muscarinic receptors is acti-
vation of the Gi/o class of G-proteins resulting in inhibi-
tion of adenylyl cyclase, whereas stimulation of M1, M3,
and M5 receptors leads to activation of the Gq/11 class of G-
proteins and stimulation of phospholipase C[2]. Mus-
carinic receptors mediate many diverse physiological
functions that are selectively mediated by different recep-
tor subtypes [3]. This is why discovery of selective ligands
is of prime importance for clinical practice. However, due
to the very conserved nature of the orthosteric binding site
of muscarinic acetylcholine receptors the selectivity of
orthosteric agonists is very poor [4]. Orthosteric antago-
nists that bind to less conserved amino acids located close
to the orthosteric binding site display better selectivity
than orthosteric agonists. Muscarinic allosteric ligands
exhibit remarkable selectivity among receptor subtypes
[5]. They interact mainly with the second and the third
extracellular loops that are much less conserved than
transmembrane segments creating the orthosteric binding
site [6-10].
The extraordinary selectivity of allosteric modulators that
is due to differences in both affinity and cooperativity [11]
has attracted attention of pharmacologists in the past dec-
ade. Somewhat paradoxically, most of originally discov-
ered and probably best studied allosteric compounds of
muscarinic receptors are neuromuscular blockers [12-14].
By definition, these are competitive nicotinic acetylcho-
line receptor antagonists but many of them have high
affinities and strong allosteric interactions, particularly at
the M2 subtype of muscarinic receptors.
In clinical practice, different competitive (nondepolariz-
ing) neuromuscular blockers are employed to induce
muscle relaxation to facilitate intubation during surgery.
The neuromuscular blocker rapacuronium was with-
drawn from clinical use due to high incidence of bron-
chospasm resulting in death [15]. Parasympathetic
innervation of airways transmits signal via postsynaptic
M3 receptors that mediate acetylcholine-induced contrac-
tion and M2 receptors that inhibit with high potency
smooth muscle relaxation mediated by increase in cyto-
plasmic cAMP [16]. M2 receptors are also located at para-
sympathetic cholinergic nerve terminals innervating
smooth muscle and their stimulation inhibits acetylcho-
line (ACh) release [17]. In functional experiments on the
guinea pig trachea preparation it was demonstrated that
rapacuronium preferentially antagonizes M2 over M3 mus-
carinic receptors [18]. In addition, involvement of allos-
teric potentiation of ACh binding to muscarinic M3
receptors in bronchospasm induced by rapacuronium was
suggested, but not proven [19]. A very recent paper con-
firmed a unique behavior of rapacuronium compared to
other skeletal muscle relaxants in vivo and demonstrated
that rapacuronium potentiates bronchoconstriction
evoked by both naturally released and exogenous acetyl-
choline, indicating an important role of postsynaptic M3
receptors [20].
Because we have been interested in investigations of posi-
tive cooperativity of allosteric ligands with ACh binding
[11,21] and allosteric agonists [22] these findings led us
to analyze in detail the interactions of rapacuronium with
acetylcholine binding and receptor activation of all sub-
types of muscarinic receptors heterologously expressed in
membranes of Chinese hamster ovary (CHO) cells. We
demonstrate that rapacuronium binds to and exhibits
negative cooperativity with ACh binding at all subtypes of
muscarinic receptors. Surprisingly, low concentrations of
rapacuronium potentiate ACh-induced signaling at the
M1, M3, and M5 receptor subtypes and accelerate ACh
binding. This striking behavior is unparallel at other neu-
romuscular blockers.
Results
Saturation binding experiments (Figure 1; Table 1) with
68 pM to 2 nM [3H]NMS in cell membranes showed sim-
ilar binding capacity (1 to 2 pmol of binding sites per mg
of protein) and affinity (equilibrium dissociation con-
stant (KD) ranging from 205 pM at M4 to 320 pM at M2
receptors) for all receptor subtypes (Figure. 1; Table 1).
Significant depletion (up to 34% at M1  for 68 pM
[3H]NMS) occurred despite the use of 0.8 ml incubation
volume in the binding assays. Thus, free concentrations of
[3H]NMS were calculated and used in Eq. 1. Saturation
binding experiments with 3.4 nM to 100 nM [3H]ACh
showed similar high affinity binding among all subtypes
with KD  around 20 nM. Rapacuronium concentration
dependently decreased affinity for [3H]NMS and [3H]ACh
at all subtypes without change in maximum binding
capacity (BMAX). Competition experiments of unlabeled
ACh vs. [3H]NMS displayed high and low binding sites for
ACh at all subtypes with higher proportion of high affinity
binding sites at even-numbered subtypes (Figure 2). Equi-
librium dissociation constants (KI) of ACh high-affinity
binding derived from competition experiments with
[3H]NMS (pKD = 7.32 ± 0.06, 7.59 ± 0.03, 7.79 ± 0.05,
7.69 ± 0.04, 7.68 ± 0.05, mean ± SE for M1 to M5 receptor)
correspond to those measured in [3H]ACh saturation
experiments (Table 1). In the presence of 10 μM GTPγS to
uncouple receptors and G-proteins ACh low affinity bind-
ing was similar at all five subtypes with equilibrium disso-
ciation constant (KI) ranging from 25.5 μM at M4 to 46.8
μM at M1.BMC Pharmacology 2009, 9:15 http://www.biomedcentral.com/1471-2210/9/15
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Saturation binding of [3H]NMS and [3H]Ach Figure 1
Saturation binding of [3H]NMS and [3H]Ach. Specific binding of [3H]NMS (circles) and [3H]ACh (squares) to mem-
branes from CHO cells expressing individual subtypes of muscarinic receptors is plotted against the concentration of free radi-
oligand. Binding of radioligand in the absence (closed symbols) and presence of 10 μM (open symbols) or 100 μM (hatched 
symbols) rapacuronium, respectively. Data are means ± SE from 3 independent experiments performed in quadruplicates. 
Curves are fits of Eq. 1 to data. Binding parameters are summarized in Table 1.
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Effects of 10 μM GTPγS on ACh competition with [3H]NMS binding Figure 2
Effects of 10 μM GTPγS on ACh competition with [3H]NMS binding. Binding of 1 nM [3H]NMS to the membranes 
from CHO cells expressing individual subtypes of muscarinic receptors in the absence (closed circles) or presence (open cir-
cles) of 1 μM GTPγS is expressed as per cent of control binding and are plotted against concentration of ACh. Data are means 
± SE of 3 independent experiments performed in quadruplicates. Binding parameters are described in the Results.
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Effects of 100 μM rapacuronium on the rate of ([3H]NMS)
dissociation were measured in membranes from CHO cell
expressing individual subtypes of muscarinic receptors
after 60 min preincubation with 1 nM [3H]NMS. Dissoci-
ation was evoked by addition of 10 μM unlabeled NMS.
Rapacuronium slowed dissociation of [3H]NMS from all
subtypes of muscarinic ACh receptors (Figure 3, Table 2).
This is an established hallmark of allosteric receptor mod-
ulation. It had the strongest effect at M2 receptors (7-fold
decrease in rate of dissociation) and weakest effect at M3
and M5  receptors (40% decrease). While dissociation
evoked by NMS was monophasic (Figure 3 closed sym-
bols) it became biphasic in the presence of 100 μM rapa-
curonium with the exception of the M5 subtype.
Displacement radioligand binding experiments with
either 20 nM [3H]ACh (Figure 4) or 1 nM [3H]NMS (Fig-
ure 5, circles) and increasing concentrations of rapacuro-
nium showed that rapacuronium binds equally well to all
five muscarinic receptor subtypes. Equilibrium dissocia-
tion constants (pKA; Table 3) for rapacuronium derived
from experiments with [3H]NMS and [3H]ACh were virtu-
ally the same with a rank order of affinity of
M2>M4>M1>M5>M3 (range from 2.6-17.8 μM). Rapacuro-
nium displayed negative cooperativity with [3H]NMS in
binding to all subtypes, as evidenced by a maximal limit
to its effects on the affinity of the radioligand that differed
as a function of radioligand concentration. These effects
were strongest at the M5 subtype (35-fold decrease in
affinity) and weakest at the M2 subtype (6.8-fold decrease
in affinity; Figure 5, closed circles). While cooperativity of
rapacuronium with high- (pα) and low-affinity (pβ) ACh
binding was essentially the same at individual subtypes
(Table 3, row-wise comparison) it was slightly different
among subtypes (e.g. 16-fold decrease in ACh low-affinity
binding at M3 receptors vs. 36-times decrease at M4 recep-
tors; Table 3, column-wise comparison).
Rapacuronium alone concentration dependently lowered
[35S]GTPγS binding to membranes (Figure 6, closed
squares; Table 4) with a maximal effect of approximately
25% at odd-numbered subtypes and 15% at even-num-
bered subtypes, with similar half-effective concentrations
(EC50) ranging from 28 μM at M2 receptors to 76 μM at M3
receptors. While the EC50  values of rapacuronium in
inhibiting [35S]GTPγS binding at individual subtypes cor-
related with affinities measured in binding experiments
with [3H]ACh (R2 = 0.76) they were lower (4- to 12-fold)
Table 1: Effects of rapacuronium on [3H]NMS and [3H]ACh saturation binding
pKD BMAX pKD'B MAX pKD'B MAX
[3H]NMS + 10 μM rapacuronium + 100 μM rapacuronium
M1 9.60 ± 0.04 1.98 ± 0.20 9.14 ± 0.03* 2.03 ± 0.15 8.73 ± 0.03* 1.85 ± 0.17
M2 9.49 ± 0.03 1.56 ± 0.16 8.92 ± 0.04* 1.62 ± 0.14 8.64 ± 0.03* 1.66 ± 0.14
M3 9.64 ± 0.05 1.64 ± 0.17 9.44 ± 0.03* 1.67 ± 0.14 8.96 ± 0.03* 1.59 ± 0.16
M4 9.69 ± 0.04 1.19 ± 0.14 9.19 ± 0.02* 1.17 ± 0.13 8.52 ± 0.06* 1.06 ± 0.10
M5 9.59 ± 0.03 1.49 ± 0.16 9.31 ± 0.02* 1.53 ± 0.15 8.46 ± 0.06* 1.33 ± 0.13
[3H]Ach + 10 μM rapacuronium + 100 μM rapacuronium
M1 7.58 ± 0.05 0.33 ± 0.05 7.12 ± 0.03* 0.33 ± 0.05 6.43 ± 0.05* 0.32 ± 0.05
M2 7.63 ± 0.03 0.80 ± 0.08 7.09 ± 0.05* 0.74 ± 0.07 6.30 ± 0.06* 0.77 ± 0.08
M3 7.67 ± 0.05 0.39 ± 0.05 7.43 ± 0.04* 0.40 ± 0.04 6.85 ± 0.03* 0.37 ± 0.05
M4 7.69 ± 0.04 0.55 ± 0.04 7.17 ± 0.03* 0.54 ± 0.05 6.41 ± 0.05* 0.47 ± 0.04
M5 7.68 ± 0.03 0.33 ± 0.06 7.43 ± 0.02* 0.33 ± 0.03 6.64 ± 0.04* 0.34 ± 0.06
Negative logarithms of equilibrium dissociation constants (pKD) and maximum binding capacities (BMAX in fmol/μg of protein) of radioligands were 
obtained from saturation experiments shown in Figure 1 by fitting Eq. 1 to the data. Values are means ± SE of fits to 3 independent experiments 
performed in quadruplicates.
*P < 0.05; significantly different from control (radioligand alone) by ANOVA and Tukey-Kramer post-test.
Table 2: Effects of rapacuronium on the rate of [3H]NMS 
dissociation.
Control + 100 μM rapacuronium
koff [min-1]k off1 [min-1]f 2 [%] koff2 [min-1]
M1 0.063 ± 0.004 0.014 ± 0.001* 14 ± 3 0.34 ± 0.05
M2 0.18 ± 0.01 0.026 ± 0.002* 23 ± 5 0.76 ± 0.11
M3 0.048 ± 0.003 0.031 ± 0.002* 20 ± 4 0.058 ± 0.009
M4 0.041 ± 0.002 0.017 ± 0.001* 6.0 ± 2.0 0.75 ± 0.11
M5 0.013 ± 0.001 0.0078 ± 0.0004*
Observed rates of [3H]NMS dissociation (koff, koff1 and koff2) and 
fraction of sites (f2) with faster dissociation (koff2) from individual 
subtypes of muscarinic receptors were obtained by fitting Eq. 7a and 
7b to data in Figure 3. Results of better fit are shown. Values are 
means ± SE of fits to 3 independent experiments performed in 
quadruplicates. *P < 0.05; significantly different from control 
([3H]NMS alone) by t-testBMC Pharmacology 2009, 9:15 http://www.biomedcentral.com/1471-2210/9/15
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Effects of 100 μM rapacuronium on dissociation of [3H]NMS binding Figure 3
Effects of 100 μM rapacuronium on dissociation of [3H]NMS binding. Binding of [3H]NMS to membranes from CHO 
cells expressing individual subtypes of muscarinic receptors at different times after the addition of 10 μM NMS (closed circles) 
or a mixture of 10 μM NMS and 100 μM rapacuronium (open circles). Specific binding is expressed as percent of binding at 
time 0. Data are means ± SE from 3 independent experiments performed in quadruplicates. Binding parameters are summa-
rized in Table 2.
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at all subtypes. We could not test the involvement of mus-
carinic receptors in the effects of rapacuronium on
[35S]GTPγS binding using orthosteric antagonists, since 10
μM NMS or 10 μM atropine by themselves decreased
[35S]GTPγS binding by more than 30% at all receptor sub-
types. Inhibitory effects of rapacuronium were not addi-
tive to those of NMS or atropine (not shown). However,
rapacuronium did not decrease [35S]GTPγS binding in
membranes from nontransfected CHO cells (Figure 6,
bottom row right).
As expected, ACh concentration-dependently stimulated
[35S]GTPγS binding to membranes from cells expressing
all individual subtypes of muscarinic receptors (Table 4
and Figure 6, closed circles). The maximal effect of ACh
(EMAX) was about two-fold increase in basal binding at
odd-numbered receptors and three-fold increase at even-
numbered receptors with a rank order of efficacy of
M2>M4>M1>M5>M3  (range from 3.12 to 1.99-fold
increase). In control conditions ACh EC50 values were
lower at even-numbered subtypes than at odd-numbered
subtypes with a rank order of potency of
M2>M4>M3>M5>M1 (range from 0.25 to 6.31 μM) (Table
5). While the EC50 of ACh-stimulated [35S]GTPγS binding
was less than that of its low-affinity binding conformation
by 178-times at M2 and 23-times at M4 receptors it was
only 7.4-, 5.4-, and 4.7-times lower at M1, M3, and M5
receptors, respectively. In comparison with its high-affin-
ity binding, the EC50 of ACh-stimulated [35S]GTPγS bind-
ing was only 10-times higher at M2 and 55-times at M4
receptors but 130-260- and 300-times higher at M1, M5
and M3 receptors, respectively. EMAX was about two-fold
increase in basal binding at odd-numbered receptors and
three-fold increase at even-numbered receptors with a
rank order of efficacy of M2>M4>M1>M5>M3 (range from
3.12 to 1.99-fold increase) (Table 5).
Measurements of ACh-stimulated [35S]GTPγS binding in
the presence of 0.1, 1 and 10 μM rapacuronium showed
differential effects of rapacuronium on receptor activation
by an orthosteric agonist at individual receptor subtypes
(Figure 6 open symbols). At even-numbered subtypes 1
μM and 10 μM rapacuronium significantly increased ACh
EC50, with lowering of EMAX at 10 μM rapacuronium.
These results are in line with the effects of rapacuronium
Table 3: Binding parameters of NMS, ACh and rapacuronium to membranes from CHO cells expressing M1 through M5 receptor 
subtypes.
[3H]NMS [3H]Ach Ach
high affinity binding low affinity binding
pKA pα pKA pα pKA pβ
M1 5.37 ± 0.03 -1.08 ± 0.05 5.37 ± 0.04 -1.30 ± 0.07 5.33 ± 0.03 -1.32 ± 0.06
M2 5.59 ± 0.03 -0.83 ± 0.07 5.55 ± 0.05 -1.46 ± 0.08 5.56 ± 0.04 -1.52 ± 0.06
M3 4.75 ± 0.04 -1.11 ± 0.05 4.80 ± 0.04 -1.26 ± 0.05 4.77 ± 0.05 -1.20 ± 0.07
M4 5.42 ± 0.04 -1.40 ± 0.04 5.41 ± 0.05 -1.51 ± 0.05 5.49 ± 0.04 -1.56 ± 0.07
M5 4.97 ± 0.04 -1.54 ± 0.05 4.92 ± 0.03 -1.34 ± 0.07 4.95 ± 0.04 -1.28 ± 0.07
Negative logarithm of equilibrium dissociation constant of rapacuronium (pKA) and factor of cooperativity (α ) between rapacuronium and 
radioligand ([3H]NMS or [3H]ACh, respectively) binding were obtained by fitting Eq. 3 to the data in Figures 4 and 5. Negative logarithm of 
equilibrium dissociation constant of rapacuronium (pKA) and factors of cooperativity (β) between rapacuronium and acetylcholine low affinity 
binding were obtained by fitting Eq. 4 to the data in Figure 5. Factors of cooperativity α and β are expressed as negative logarithms so that negative 
values represent negative cooperativity. Values are means ± SE of fits to 3 independent experiments performed in quadruplicates.
Effects of rapacuronium on high-affinity [3H]ACh binding Figure 4
Effects of rapacuronium on high-affinity [3H]ACh 
binding. Binding of 20 nM [3H]ACh to membranes from 
CHO cells expressing individual subtypes of muscarinic 
receptors (circles, M1; squares, M2; diamonds, M3; up-trian-
gles, M4; down-triangles, M5) was determined in the presence 
of rapacuronium at the concentrations indicated on the x-
axis and is expressed as percent of specific binding in the 
absence of rapacuronium. Data are means ± SE from 3 inde-
pendent experiments performed in quadruplicates. Curves 
are fits of Eq. 3 to data. Binding parameters are summarized 
in Table 3.
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Effects of rapacuronium on low-affinity ACh binding and [3H]NMS binding Figure 5
Effects of rapacuronium on low-affinity ACh binding and [3H]NMS binding. Binding of 1 nM [3H]NMS to membranes 
from CHO cells expressing individual subtypes of muscarinic receptors was measured in the presence of rapacuronium at the 
concentrations indicated on the x-axis. Data are expressed as percent of specific binding in the absence of rapacuronium. Sym-
bols represent binding of [3H]NMS (circles), and [3H]NMS in the presence of 10 μM GTPγS and 100 μM (squares) or 200 μM 
(triangles) ACh. Binding of [3H]NMS was decreased by 100 μM ACh to 71, 64, 59, 60 and 56% and by 200 μM ACh to 55, 47, 
42, 43 and 39% at M1 to M5 receptors, respectively. Bigger divergence of curves denotes stronger negative cooperativity 
between ACh and rapacuronium binding. Data are means ± SE from 3 independent experiments performed in quadruplicates. 
Curves are fits of Eq. 3 (circles) and Eq. 4 (squares and triangles) to data prior to normalization. Binding parameters are sum-
marized in Table 3.
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on ACh binding. In contrast, the effects of rapacuronium
on activation of odd-numbered subtypes were more com-
plex. At these subtypes rapacuronium had the strongest
effect on activation of the M3 subtype. At this subtype 0.1
and 1 μM rapacuronium caused a significant 2-fold
decrease in ACh EC50 and approximately 60% and 35%
increase in EMAX, respectively. Rapacuronium at 10 μM
increased ACh EC50 by about 3-fold without a significant
change in EMAX. Rapacuronium (0.1 - 10 μM) had no
effect on ACh efficacy at the M1 and M5 subtypes but
decreased the EC50  of ACh in stimulating [35S]GTPγS
binding by 1.5- and 4-fold, respectively, at concentrations
of 0.1 and 1 μM. However, this effect was not evident at
10 μM rapacuronium (Figure 6).
Kinetics of [35S]GTPγS binding to membranes from CHO-
M3 cells (where rapacuronium has the most pronounced
effects) were measured after 5 min preincubation with 5
μM GDP and 60 min with 1 μM rapacuronium followed
by simultaneous addition of [35S]GTPγS and ACh, with or
without rapacuronium (Figure 7). Under basal conditions
([35S]GTPγS + buffer, Figure 7, closed circles) [35S]GTPγS
bound to membranes with an observed rate constant
(kobs) of 0.0269 ± 0.0022 min-1. Ten μM ACh accelerated
the rate of [35S]GTPγS binding to 0.0583 ± 0.047 min-1
(Figure 7, closed squares) and 1 μM rapacuronium further
increased the rate to 0.166 ± 0.013 min-1 (Figure 7, open
squares). While 10 μM ACh alone produced only 2-fold
increase in [35S]GTPγS binding at 5 min incubation it
caused nearly 5-fold increase in the presence of 1 μM rapa-
curonium. Estimated [35S]GTPγS equilibrium binding
(Beq) was the same for all 3 treatments (10,000 ± 300,
10,100 ± 100, and 9,980 ± 120 cpm per well for basal,
ACh and ACh with rapacuronium, respectively; mean ±
SE, n = 3). Rapacuronium alone slightly decreased the rate
of [35S]GTPγS binding (Figure 7, open circles).
Effects of rapacuronium on the association rate of high-
affinity (40 nM) [3H]ACh binding were measured after 60
min preincubation of membranes with rapacuronium.
Association of [3H]ACh is complex and consists of an ini-
tial very fast step in the range of seconds followed by a
slower phase (Figure 8, first time point is 5 s). Under con-
trol conditions (Figure 8, closed circles) the slower phase
of [3H]ACh association was characterized by an observed
rate (kobs) in the range of 1.43 (M3) to 3.5 (M5) min-1.
While the presence of 1 μM rapacuronium had marginal
effects on [3H]ACh association (Figure 8, open circles) the
association binding curve became more complex and
showed a peak in the presence of 10 μM rapacuronium
(Figure 8, hatched circles). This peak occurred at 15 to 20
seconds at odd-numbered receptors and at 30 to 50 sec-
onds at the M4 and around 90 seconds at the M2 receptor.
Peak binding was higher than control binding at odd-
numbered receptors, the same as control binding at M4
and lower than control binding at M2  receptor. An
increase in [3H]ACh binding after extended incubation
(hours) occurred at M3, M4, and M5 receptors.
Effects of 10 μM rapacuronium on the dissociation rate of
high-affinity [3H]ACh binding were measured after 60
min preincubation of membranes with 40 nM [3H]ACh.
Dissociation was evoked by the addition of unlabeled
ACh at a final concentration of 40 μM, either alone or
mixed with 10 μM rapacuronium (Figure 9, Table 6).
[3H]ACh dissociation curves consisted of a very rapid
phase followed by a slow one, both in the absence (Figure
9, closed circles) and in the presence (Figure 9, open and
hatched circles) of rapacuronium. The slower phase of
[3H]ACh dissociation displayed a rate (koff) in the range of
0.112 (M5) to 0.507 (M2) min-1 (Figure 9, closed circles).
While effects of 1 μM rapacuronium on [3H]ACh dissoci-
ation were marginal, 10 μM rapacuronium either acceler-
ated (odd-numbered), did not change (M4) or slowed
(M2) the rate of [3H]ACh dissociation (Figure 9, hatched
circles).
The effects of rapacuronium and the two prototypic allos-
teric modulators alcuronium and gallamine on ACh-stim-
ulated [35S]GTPγS binding and kinetics of [3H]ACh
binding were compared at M3 receptors where the effects
of rapacuronium were most pronounced. Measurements
of ACh-stimulated [35S]GTPγS binding in the presence of
1 and 10 μM alcuronium or 1 and 10 μM gallamine,
showed a small concentration-dependent increase in the
EC50 of ACh without change in EMAX values (Figure 10,
Table 7). Both alcuronium and gallamine concentration
dependently slowed [35S]GTPγS association stimulated by
10 μM ACh. At 10 μM concentrations they also decreased
[35S]GTPγS equilibrium binding (Figure 10, Table 7).
Table 4: Direct effects of rapacuronium on [35S]GTPγS binding
M1 M2 M3 M4 M5
pEC50 4.30 ± 0.04 4.55 ± 0.04 4.12 ± 0.03 4.44 ± 0.04 4.21 ± 0.04
EMAX 0.76 ± 0.08 0.84 ± 0.06 0.75 ± 0.07 0.86 ± 0.06 0.75 ± 0.07
Negative logarithms of half effective concentrations (pEC50) and EMAX of rapacuronium on [35S]GTPγS binding were obtained by fitting Eq. 5 to the 
data from the measurements of [35S]GTPγS binding in the presence of rapacuronium in concentrations ranging from 10-8 to 10-3 M normalized to 
the absence of rapacuronium (Figure 6, open squares). Values are means ± SE of fits to 3 independent experiments performed in quadruplicates.BMC Pharmacology 2009, 9:15 http://www.biomedcentral.com/1471-2210/9/15
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Effects of rapacuronium on ACh-induced [35S]GTPγS binding to membranes Figure 6
Effects of rapacuronium on ACh-induced [35S]GTPγS binding to membranes. Membranes from CHO cells express-
ing individual subtypes of muscarinic receptors or nontransfected CHO-K1 cells were preincubated for 60 min with buffer 
(closed symbols) or with rapacuronium (open symbols). [35S]GTPγS binding was induced by rapacuronium alone (closed 
squares), ACh alone (closed circles), or by ACh in the presence of rapacuronium (0.1 μM (open circles), 1 μM (open squares), 
or 10 μM (open triangles)). Data are expressed as fold increase of basal [35S]GTPγS binding and are presented as means ± SE 
from 3 independent experiments performed in quadruplicates. Curves are fits of Eq. 5 to data. Parameters are summarized in 
Tables 4 and 5.
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Alcuronium and gallamine slowed down association of
40 nM [3H]ACh and decreased its equilibrium binding at
M3 receptors (Figure 10, Table 7).
Discussion
Our results clearly demonstrate that the neuromuscular
blocker rapacuronium binds to all muscarinic receptor
subtypes at physiologically relevant concentrations [18]
and displays micromolar affinity and slight selectivity
towards M2 receptor. This selectivity is smaller than that of
other neuromuscular blockers such as alcuronium,
gallamine and pancuronium [23, 24, Jakubík, unpub-
lished data]. Like the majority of this class of compounds,
rapacuronium acts as a negative allosteric modulator
(alters dissociation kinetics and incompletely inhibits
binding of orthosteric ligands) with respect to binding of
both the natural agonist ACh (Figures 1, 4, 5, 8 and 9) and
the classical antagonist NMS (Figures 1, 3, and 5). Rapa-
curonium exhibits complex effects on the kinetics of ACh
binding (Figures 8 and 9) and subsequent receptor activa-
tion estimated from stimulation of [35S]GTPγS binding
(Figures 6 and 7). Functional effects differ from those of
the prototypic negative allosteric modulators alcuronium
and gallamine (Figure 10, Table 7).
Table 5: Effects of rapacuronium on ACh-stimulated [35S]GTPγS binding
Acetylcholine + 0.1 μM rapacuronium + 1 μM rapacuronium + 10 μM rapacuronium
pEC50 EMAX pEC50 EMAX pEC50 EMAX pEC50 EMAX
M1 5.20 ± 0.05 2.23 ± 0.08 5.41 ± 0.04* 2.35 ± 0.12 5.78 ± 0.04* 2.28 ± 0.12 5.22 ± 0.05 2.27 ± 0.11
M2 6.61 ± 0.03 3.12 ± 0.12 6.65 ± 0.03 3.10 ± 0.15 5.92 ± 0.05* 2.93 ± 0.13 5.67 ± 0.07* 2.46 ± 0.18*
M3 5.31 ± 0.05 2.12 ± 0.08 5.65 ± 0.04* 2.78 ± 0.11* 5.66 ± 0.04* 2.52 ± 0.08* 4.83 ± 0.05* 2.12 ± 0.09
M4 5.95 ± 0.04 2.93 ± 0.15 5.93 ± 0.04 2.95 ± 0.11 5.59 ± 0.05* 2.80 ± 0.12 5.12 ± 0.05* 2.32 ± 0.16*
M5 5.26 ± 0.05 1.99 ± 0.08 5.45 ± 0.04* 2.10 ± 0.09 5.82 ± 0.04* 2.04 ± 0.09 5.29 ± 0.05 2.22 ± 0.09
Negative logarithms of half effective concentrations (pEC50) and maximum stimulatory effect (EMAX) of acetylcholine on [35S]GTPγS binding in the 
absence or presence of the indicated concentrations of rapacuronium were obtained by fitting Eq. 5 to the data in Figure 6. Values are means ± SE 
of fits to 3 independent experiments performed in quadruplicates. *P < 0.05; significantly different from control (Ach alone) by ANOVA and Tukey-
Kramer post-test.
Effects of rapacuronium on kinetics of [35S]GTPγS binding Figure 7
Effects of rapacuronium on kinetics of [35S]GTPγS binding. Membranes were preincubated for 60 min in the presence 
(open symbols) or absence (closed symbols) of 1 μM rapacuronium. Then [35S]GTPγS was added simultaneously with buffer 
(circles) or 10 μM ACh (squares). Incubations were terminated at the times indicated on the x-axis. The increase of specific 
[35S]GTPγS binding is expressed as fmol per μg of protein (left) and as fold increase of specific binding under basal conditions 
(right). Data are means ± SE of values from 3 independent experiments performed in quadruplicates.BMC Pharmacology 2009, 9:15 http://www.biomedcentral.com/1471-2210/9/15
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Effects of rapacuronium on [3H]ACh association Figure 8
Effects of rapacuronium on [3H]ACh association. Membranes from CHO cells expressing individual subtypes of mus-
carinic receptors were preincubated 60 min with buffer (closed circles) or 1 μM (open circles) or 10 μM (hatched circles) rapa-
curonium and then [3H]ACh was added to a final concentration of 40 nM at time 0. Incubations were terminated at the times 
indicated on the x-axis. Specific [3H]ACh binding is expressed as fmol per mg of proteins. Data are means ± SE of values from 
3 independent experiments performed in quadruplicates. Binding parameters are shown in Table 6.
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Our observation of an allosteric mode of interaction
between rapacuronium and muscarinic receptors is in
agreement with reported slowing-down of NMS dissocia-
tion from M2 and M3 receptors by this drug [19]. The
observed biphasic dissociation of NMS under non-equi-
librium conditions in the presence of an allosteric modu-
lator such as rapacuronium was described earlier [24].
Inverse receptor agonism by rapacuronium
Rapacuronium alone decreases [35S]GTPγS binding. This
effect is mediated by muscarinic receptors because it is not
observed in membranes prepared from a native CHO cell
line that does not express muscarinic receptors and thus
cannot be explained by nonspecific effects on cell mem-
branes. Instead, this effect can be related to an inverse ago-
nistic effect of rapacuronium itself on constitutive
receptor activity. This view is supported by previous dem-
onstration of constitutive activity of muscarinic receptors
[25,26] and by finding that the orthosteric antagonists
NMS and atropine also decrease [35S]GTPγS binding when
applied alone [22,27]. In addition, both agonistic and
inverse agonistic effects of allosteric modulators have
already been observed [27,28].
Allosteric modulation of receptor activation by 
rapacuronium
Both [3H]ACh saturation binding experiments (Figure 1)
and ACh vs. [3H]NMS competition experiments (Figure 2)
show ACh high affinity binding in the nanomolar range
without selectivity towards any of muscarinic receptor
subtypes. The affinities of ACh at M2 and M4 receptors
reported in this study are within the range of published
values, being lower than those published by Lazareno et
al. [11] but higher than the values reported by Haga et al.
[29] or Gurwitz et al. [30]. This divergence is likely due to
the dependence of the affinity of acetylcholine at its high-
affinity site on many factors (e.g. receptor source, prepara-
tion, concentration of ions (mainly Mg2+, Na+), residual
concentration of GDP, temperature, etc.). Similarly, we
found no subtype differences in ACh low affinity binding,
which is in accordance with our previous studies [21].
Despite lack of binding selectivity, the potency and effi-
cacy of ACh in stimulating [35S]GTPγS binding are signif-
icantly higher at even-numbered than at odd-numbered
subtypes. In other words, the M2 and M4 subtypes that
preferentially couple with Gi/o G-proteins display better
coupling and larger receptor reserve than the M1, M3, and
M5 subtypes that preferentially couple with Gq/11 G-pro-
teins. Despite accumulating evidence for the existence of
agonist-specific conformations of muscarinic and other
G-protein-coupled receptors [31-33] it is generally
accepted that the change in agonist potency in receptor
activation follows a change in the affinity of its binding
induced by an allosteric modulator. Thus, negative coop-
erativity between the allosteric modulator and the bind-
ing of an orthosteric agonist would lead to lower potency
of agonist (e.g. pioneering experiments with gallamine of
Clark and Mitchelson [12]) and positive cooperativity
would result in higher potency of agonist [11,34]. Rapa-
curonium behaves in accordance with this view in case of
the M2 and M4 subtypes. However, at the M1, M3 and M5
receptor subtypes, rapacuronium up to a concentration of
10 μM either increases or does not alter ACh potency or
efficacy in inducing [35S]GTPγS binding (Figure 6),
despite clear negative cooperativity with ACh binding
(Figures 4 and 5). Although this observation may appear
surprising at first glance it is perfectly in agreement with
the hypothesis of multiple receptor conformations
induced by orthosteric and allosteric ligands, and with the
existence of conformations that exhibit low affinity for
agonist binding but nevertheless activate second messen-
ger pathways [26,31,35,36].
Kinetics of functional response
Analysis of the kinetics of [35S]GTPγS binding shows that
the facilitatory effects of rapacuronium on ACh-induced
responses are evident after brief incubations (lasting min-
utes, Figure 7). This suggests that the facilitating effects of
rapacuronium on ACh-induced response are a conse-
quence of altered receptor kinetics rather than a change in
agonist affinity at equilibrium. Extended time of incuba-
tion during which binding of ligands equilibrates may
thus obscure the initial transient potentiation. Analysis of
kinetics of ACh binding (Figures 8 and 9) showed that
rapacuronium affects ACh kinetics differently than those
of NMS. While rapacuronium slows down NMS associa-
tion and dissociation at all receptor subtypes (Figure 3) it
accelerates ACh association and dissociation at odd-num-
bered subtypes (Figures 8 and 9). Thus, rapacuronium
doubles the magnitude of ACh binding at 15 seconds at
these receptors such that association after 15 seconds is
twice as much in the presence of rapacuronium. This
effect, however, is counterbalanced by accelerated dissoci-
ation, resulting in an overall decrease in ACh affinity (neg-
Table 6: Effects of rapacuronium on the rate of [3H]ACh 
association and dissociation
40 nM [3H]ACh + 10 μM rapacuronium
kobs [min-1]k off [min-1]k off [min-1]
M1 2.74 ± 0.25 0.294 ± 0.015 0.917 ± 0.046*
M2 1.58 ± 0.14 0.507 ± 0.025 0.245 ± 0.012*
M3 1.43 ± 0.13 0.226 ± 0.011 0.923 ± 0.046*
M4 2.01 ± 0.18 0.373 ± 0.019 0.355 ± 0.018
M5 3.50 ± 0.31 0.112 ± 0.006 0.378 ± 0.019*
Observed rates of association (kobs) of 40 nM [3H]ACh with and 
dissociation (koff) from individual subtypes of muscarinic receptors 
were obtained by fitting Eq. 6 to data in Figure 8 and Eq. 7c to data in 
Figure 9. Values are means ± SE of fits to 3 independent experiments 
performed in quadruplicates. *P < 0.05; significantly different from 
control ([3H]ACh alone) by t-test.BMC Pharmacology 2009, 9:15 http://www.biomedcentral.com/1471-2210/9/15
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Effect of rapacuronium on the time course of [3H]ACh dissociation Figure 9
Effect of rapacuronium on the time course of [3H]ACh dissociation. Membranes from CHO cells expressing individ-
ual subtypes of muscarinic receptors were prelabeled with 40 nM [3H]ACh for 60 min. At time zero 40 μM unlabeled ACh was 
added alone (closed circles) or as a mixture with 1 μM rapacuronium (open circles) or 10 μM rapacuronium (hatched circles). 
Incubations were terminated at the times indicated on the x-axis. Specific [3H]ACh binding is expressed as percent of specific 
binding at time 0 on x-axis. Data are means ± SE of values from 3 independent experiments performed in quadruplicates. Bind-
ing parameters are shown in Table 6.
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ative cooperativity). Although combination of negative
binding cooperativity on the one hand and acceleration of
binding on the other could in principle be interpreted
within the frame of the ternary receptor model. However,
data of association and dissociation of ACh in the absence
of rapacuronium do not conform to a simple bi-molecu-
lar interaction. As a result, the interaction between ACh
and rapacuronium at muscarinic receptors is more com-
plex and may involve allosteric extension of the tandem
two-site model [37,38]. Theoretically, this extension of
the model allows for coexistence of positive cooperativity
between rapacuronium and the initial step of ACh bind-
ing and overall negative binding cooperativity under equi-
librium. An enigmatic feature of our data, however, is that
low concentrations of rapacuronium (0.1 and 1 μM) that
do not affect the the rate of binding of ACh or its affinity
at equilibrium at odd numbered subtypes leads to an
increase in both potency and efficacy of ACh in receptor
activation. Theoreticaly, allosteric extension of tandem
two-site model allows for positive cooperativity between
rapacuronium and ACh initial binding step in overall neg-
ative binding cooperativity under equilibrium and tran-
sient binding of these sub-threshold concentrations.
However, these concentrations of rapacuronium had no
effect on ACh association in binding experiments (Figure
8, open circles). One possible explanation is that ACh
bound to a peripheral site (of tandem two-site binding) is
lost during filtration but is well reflected and amplified in
GTPγS binding that is pseudo-irreversible. A more specu-
lative explanation assumes that rapacuronium at sub-
micromolar concentrations binds to another site on the
receptor and facilitates receptor activation by ACh without
significant interference with radioligand binding. This
facilitatory effect is overcome at high concentrations of
rapacuronium by negative cooperativity in binding of
ACh induced by binding of rapacuronium to an allosteric
binding site. A latent further increase in ACh binding after
5 min in the presence of 10 μM rapacuronium (Figure 8,
hatched circles) suggests an even more complex mecha-
nism of interaction of rapacuronium wih the receptor.
Modeling of such complex kinetics would require a model
even more sophisticated than ternary extension of the tan-
dem-two site model [38]. Additionally, differential effects
of low concentrations of rapacuronium (1 μM and lower)
on receptor binding and function would require inclusion
of receptor activation (probably with several ligand-spe-
cific activation states) in the model and therefore renders
modeling unachievable.
Comparison of the effects of rapacuronium with those of
the prototypic allosteric modulators alcuronium and
gallamine (Figures eleven and twelve) on M3 receptors
shows that acceleration of ACh kinetics is unique to rapa-
curonium among negative allosteric modulators. To our
knowledge this is the first report of acceleration of binding
of an orthosteric ligand by a negative allosteric modula-
tor. This highlights unpredictability of kinetics of allos-
teric modulation based on compounds with similar
behavior observed under equilibrium.
Physiological implications
Our observations are consistent with functional ex vivo
and in vivo physiological experiments demonstrating an
increase of acetylcholine-evoked muscle contraction of
guinea pig trachea rings by rapacuronium [18-20].
Although they confirm proposed allostetic interaction
between rapacuronium and ACh [19] they do not con-
form to the proposed positive binding cooperativity at the
M3 receptor subtype. Although rapacuronium at concen-
trations below 10 μM binds to and decreases the affinity
of acetylcholine at equilibrium at all subtypes of mus-
carinic receptors, it accelerates association of ACh and
enhances its potency and efficacy in functional responses
at the M3 receptor as evident from [35S]GTPγS binding.
The initial acceleration of the rate of association of ACh
Table 7: Effects of alcuronium and gallamine on ACh-stimulated [35S]GTPγS binding at M3 receptors.
40 nM [3H]ACh binding [35S]GTPγS binding
kobs [min-1]B eq [fmol/mg prot.] kobs [min-1]B eq [fmol/μg prot.] pEC50 EMAX [fold over 
basal]
Control 1.28 ± 0.06 357 ± 17 0.0579 ± 0.0013 530 ± 37 5.18 ± 0.03 2.94 ± 0.12
+ 1 μM alcuronium 1.00 ± 0.02* 262 ± 10* 0. 0509 ± 0.0017* 496 ± 33 5.03 ± 0.02* 2.90 ± 0.14
+ 10 μM alcuronium 0.888 ± 0.012* 199 ± 12* 0.0481 ± 0.0021* 428 ± 39* 4.82 ± 0.02* 2.87 ± 0.12
+ 1 μM gallamine 1.06 ± 0.02* 246 ± 10* 0.0525 ± 0.0015* 479 ± 29 5.01 ± 0.04* 2.83 ± 0.12
+ 10 μM gallamine 0.783 ± 0.009* 191 ± 8* 0.0492 ± 0.0015* 442 ± 27* 4.82 ± 0.01* 2.73 ± 0.15
Values of observed rates of association (kobs) and equilibrium binding (Beq) of 40 nM [3H]ACh with M3 receptors were obtained by fitting Eq. 6 to 
data in Figure 10 (top). Values of kobs and Beq of 200 pM [35S]GTPγS with M3 receptors were obtained by fitting Eq. 6 to data in Figure 10 (middle). 
Negative logarithms of half effective concentrations (pEC50) and maximum stimulatory effect (EMAX) of acetylcholine on [35S]GTPγS binding in the 
absence or presence of the indicated concentrations of alcuronium or gallamine were obtained by fitting Eq. 5 to the data in Figure 10 (bottom). 
Values are means ± SE of fits to 3 to 6 independent experiments performed in quadruplicates. *P < 0.05; significantly different from control (ACh 
alone) by ANOVA and Tukey-Kramer post-test.BMC Pharmacology 2009, 9:15 http://www.biomedcentral.com/1471-2210/9/15
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Effects of alcuronium and gallamine on [3H]ACh binding and ACh-stimulated [35S]GTPγS binding to M3 membranes Figure 10
Effects of alcuronium and gallamine on [3H]ACh binding and ACh-stimulated [35S]GTPγS binding to M3 mem-
branes. Effects of the reference allosteric modulators alcuronium (left) and gallamine (right) on kinetics of [3H]ACh binding 
(top) and ACh-stimulated [35S]GTPγS binding (middle) and concentration response of [35S]GTPγS binding to ACh stimulation 
(bottom) at M3 receptors were measured after preincubation of membranes for 60 min with buffer (closed circles) or with 1 
μM (open squares) or 10 μM (open triangles) rapacuronium. Then either [3H]ACh (top) or [35S]GTPγS simultaneously with 10 
μM ACh (middle and bottom) was added. Incubation was terminated at the times indicated on the x-axis (top and middle) or 
after 20 min (bottom). Binding is expressed as fmol per μg of protein of specific [3H]ACh (top) or [35S]GTPγS (middle) binding 
or as fold increase of basal [35S]GTPγS binding (bottom). Data are means ± SE from 3 to 6 independent experiments per-
formed in quadruplicates. Parameters are summarized in Table 7.
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would potentiate fast responses such as bronchial smooth
muscle contractions mediated by transient actions of ace-
tylcholine at M3 receptors [16]. In contrast, rapacuronium
at clinically relevant concentrations strongly reduces the
affinity of binding of ACh and also its potency and effi-
cacy in activating M2 receptors. This pattern of effects
should lead to an increase in ACh release by interrupting
its M2 receptor-mediated presynaptic autoinhibition [17]
and to the inhibition of postsynaptic M2 receptor-medi-
ated muscle relaxation. In contrast, the decrease of ACh
affinity at the M2 and M4 subtypes is accompanied by a
decrease in both potency and efficacy of stimulating
[35S]GTPγS binding. The synergistic effects of negative
functional modulation of pre- and postsynaptic M2 recep-
tors and positive functional modulation of postsynaptic
M3 receptors can explain the fatal bronchospasm caused
by rapacuronium in human.
Conclusions
Although rapacuronium exerts negative cooperativity
with binding of ACh to all muscarinic receptor subtypes at
equilibrium it accelerates the rate of ACh binding at odd
numbered subtypes. At concentrations below 10 μM, it
increases the potency and efficacy of ACh in increasing the
rate of [35S]GTPγS binding at odd-numbered subtypes.
The time between acetylcholine release and termination
of its action by acetylcholinesterase is in the range of a
fraction of a second. Therefore, the effects of allosteric
modulators in the early non-equilibrium stage of receptor
signaling are therapeutically more important than effects
on acetylcholine equilibrium binding, as the latter condi-
tions do not occur in vivo. Our study demonstrates a case
of dichotomous effects of the allosteric modulator rapa-
curonium on ACh equilibrium binding on the one hand
and on the kinetics of ACh binding on the other. Our
observations emphasize the necessity to employ fast func-
tional assays in screening for potential allosteric modula-
tors of neurotransmission that much better simulate
physiological conditions than long-lasting equilibrium
binding experiments.
Methods
Materials
The radioligands [3H]-N-methylscopolamine chloride
([3H]NMS) and guanosine-5'-γ[35S]thiotrisphosphate
([35S]GTPγS) were from Amersham (UK), [methyl-
3H]acetylcholine iodide ([3H]ACh) was from ARC (St.
Louis, MO). Carbachol, dithiotreitol, gallamine triethio-
dide (TLC >98%), guanosine-5'-bis-phosphate (GDP),
guanosine-5'-γS-thiotrisphosphate (GTPγS), and N-meth-
ylscopolamine chloride (NMS) were from Sigma (St.
Louis, MO). Rapacuronium (Organon, West Range, NJ)
was kindly provided by Prof. Emala, Columbia Univer-
sity, New York, NY. Alcuronium was kindly provided by F.
Hoffmann-la Roche Ltd., Basle, Switzerland. CHO cells
stably expressing individual subtypes of muscarinic recep-
tors were provided by Dr. T.I. Bonner (National Institutes
of Health, Bethesda, MD).
Cell culture and membrane preparation
Chinese hamster ovary cells stably transfected with the
human M1 to M5 muscarinic receptor genes were grown to
confluence in 75 cm2  flasks in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine
serum and 2 million cells were subcultured to 100 mm
Petri dishes. Medium was supplemented with 5 mM
butyrate for last 24 hours of cultivation. Cells were
detached by mild trypsinization on day 5 after subculture.
Detached cells were washed twice in 50 ml of phosphate-
buffered saline and 3 min centrifugation at 250 × g.
Washed cells were diluted in ice cold homogenization
medium (100 mM NaCl, 20 mM Na-HEPES, 10 mM
EDTA; pH = 7.4) and homogenized on ice by two 30 s
strokes using Polytron homogenizer (Ultra-Turrax; Janke
& Kunkel GmbH & Co. KG, IKA-Labortechnik, Staufen,
Germany) with a 30 s pause between strokes. Cell
homogenates were centrifuged for 30 min at 30,000 × g.
Supernatants were discarded, pellets resuspended in fresh
incubation medium (100 mM NaCl, 20 mM Na-HEPES,
10 mM MgCl2; pH = 7.4) and centrifuged again. Resulting
membrane pellets were kept at -20°C until assayed, for 10
weeks at maximum.
Radioligand binding
All radioligand binding experiments were carried out on
membranes in 96-well plates at 30°C in the incubation
medium described above supplemented with freshly pre-
pared dithiothreitol at a final concentration of 1 mM,
essentially as described by Jakubík et al. [23]. Membranes
at concentrations 4, 50 and 100 μg of protein per well
were used for [35S]GTPγS, [3H]NMS and [3H]ACh bind-
ing, respectively. Final volume was 200 μl, except for
[3H]NMS saturation binding that was done in 0.8 ml vol-
ume. High affinity acetylcholine and NMS binding was
measured directly using [3H]ACh and [3H]NMS, respec-
tively. Low affinity acetylcholine binding to muscarinic
receptors was determined by the ability of unlabeled ACh
to decrease binding of 1 nM [3H]NMS in the presence of
10 μM GTPγS. Nonspecific binding was determined in the
presence of 10 μM NMS. Incubation with [3H]ACh or
[3H]NMS lasted 60 min and was terminated by fast filtra-
tion and washing with ice cold water through Whatman
GF/F glass-fiber filters (Whatman) using a Tomtech Mach
III cell harvester (Perkin Elmer, USA). Filtration and wash-
ing lasted 4 s for [3H]ACh and 9 s for [3H]NMS (wash-
aspirate button times). Six concentrations of [3H]NMS
were used in saturation experiments (68 pM to 2000 pM
[3H]NMS in the absence of rapacuronium and 189 pM to
5000 pM [3H]NMS in its presence). Corresponding con-
centrations of [3H]ACh were 3.4 nM to 100 nM [3H]AChBMC Pharmacology 2009, 9:15 http://www.biomedcentral.com/1471-2210/9/15
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in the absence of paracuronium and 7 nM to 200 nM
[3H]ACh in its presence. Effects of rapacuronium on ace-
tylcholine high affinity binding was measured as a change
in [3H]acetylcholine binding after 60 min prelabeling
with 20 nM [3H]ACh followed by addition of rapacuro-
nium and incubation for additional 3 hours. Effects of
rapacuronium on ACh low affinity binding was deter-
mined as a change in [3H]NMS binding in the presence of
10 μM GTPγS after 60 min prelabeling of membranes with
1 nM [3H]NMS followed by addition of ACh with or with-
out rapacuronium and additional 3 hours of incubation.
Effects of rapacuronium on [3H]ACh association was
measured after 60 min preincubation with 10 μM rapa-
curonium. When kinetics of association were measured
Bio-Tek μFill (Bio-Tek Instruments, Winooski, VT) was
programmed for addition of hot ligand at appropriate
times before filtration. Effects of rapacuronium on disso-
ciation of [3H]NMS or [3H]ACh binding was measured by
addition of 10 or 100 μM rapacuronium to a mixture with
unlabeled ligand (10 μM NMS or 40 μM ACh) to initiate
dissociation.
For determination of [35S]GTPγS binding to G-proteins in
membranes a final concentration of 200 pM (M1, M3 and
M5  receptors) or 500 pM (M2  and M4  receptors) of
[35S]GTPγS was used. Incubation medium was supple-
mented with 5 μM (M1, M3 and M5 receptors) or 50 μM
(M2 and M4 receptors) GDP. Nonspecific binding was
determined in the presence of 1 μM unlabeled GTPγS.
When effects of rapacuronium on ACh-stimulated
[35S]GTPγS binding was measured rapacuronium was
added to membranes 60 min prior to ACh and
[35S]GTPγS. Incubation with [35S]GTPγS was carried out
for 20 min and free ligand was removed by filtration as
described above. Filtration and washing with ice-cold
water lasted for 9 s (wash-aspirate button time).
After filtration filters were dried in vacuum for 1 h while
heated at 80°C and then solid scintillator Meltilex A was
melted on filters (105°C, 90 s) using a hot plate. After
cooling the filters were counted using a Wallac Microbeta
scintillation counter.
Data analysis
In general binding data were analyzed as described in
Jakubík et al. [21]. Data were preprocessed by Open Office
3.0 http://www.openoffice.org and subsequently ana-
lyzed by Grace 5.1.18 http://plazma-gate.weizman.ac.il/
and statistics package R http://www.r-project.org on Man-
driva distribution of Linux.
The following equations were fitted to data:
Saturation of radioligand binding
y, binding of radioligand ([3H]NMS or [3H]acetylcholine)
at free radioligand (after correction for depletion) concen-
tration x; BMAX, maximum binding capacity; KD, equilib-
rium dissociation constant.
Competition with [3H]NMS binding
y, binding of [3H]NMS at a concentration of displacer x
normalized to binding in the absence of displacer; IC50,
concentration causing 50% decrease in binding.
Equilibrium dissociation constant of displacer (Ki) was
calculated according Cheng and Prusoff [39].
Allosteric interaction between rapacuronium and
[3H]NMS or [3H]acetylcholine high affinity binding
y, binding of radioligand ([3H]NMS or [3H]acetylcholine)
in the presence of rapacuronium at concentration x nor-
malized to the absence of rapacuronium; [L] concentra-
tion of radioligand; KD, equilibrium dissociation constant
of radioligand; KA; equilibrium dissociation constant of
rapacuronium; α, factor of cooperativity between radioli-
gand and rapacuronium [40]. Cooperativity factor greater
than 1 denotes negative cooperativity and less than 1 pos-
itive cooperativity. Due to its log-normal error distribu-
tion factors of cooperativity are expressed as negative
logarithms (pα) through the manuscript so negative val-
ues denotes negative cooperativity and positive value
denotes positive cooperativity.
Allosteric interaction between rapacuronium and acetyl-
choline low affinity binding
y, binding of [3H]NMS in the presence of rapacuronium at
concentration x normalized to the absence of rapacuro-
nium; [N] concentration of [3H]NMS; KD, equilibrium
dissociation constant of [3H]NMS; [A], concentration of
acetylcholine; KI, equilibrium dissociation constant form
Eq. 2; KA; equilibrium dissociation constant of rapacuro-
nium from Eq. 3; α, factor of cooperativity between
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[3H]NMS and rapacuronium from Eq. 3; β, factor of coop-
erativity between rapacuronium and acetylcholine [21].
Concentration-response
y, radioactivity in the presence of agonist at concentration
x normalized to radioactivity in the absence of agonist;
EMAX, maximal increase by agonist; EC50, concentration of
agonist producing 50% of maximal effect; nH, Hill coeffi-
cient.
Time course of association
y, radioligand binding at time x; kobs, observed rate of
association; equilibrium binding Beq = Bottom + Span.
Time course of dissociation
or
or
y, radioligand binding at time x normalized to binding at
time 0; koff1 and koff2, dissociation rate constants; f2, frac-
tion of binding site with dissociation rate constant koff2.
When both Eq. 7a and 7b were fitted to data the better fit
was chosen based on sum of squares F-test and runs test.
For fitting parameter estimates close to one expected were
entered manually, parameters were constrained to reason-
able range, the tolerance value was set to 0.01 and itera-
tion steps to 30. Initial values of slope factors were always
1 constrained to 0.8 to 1.2 range.
List of abbreviations
Ach: acetylcholine; ANOVA: analysis of variance; CHO:
Chinese hamster ovary; GTPγS: guanosine 5'-O-(3-
thio)triphosphate; NMS: N-methylscopolamine; TCM:
ternary complex model.
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